Targeting Mitophagy to Slow Aging: Pathways, Drugs, and Exercise
A comprehensive review reveals how selectively clearing damaged mitochondria via autophagy could be a powerful anti-aging strategy.
Summary
This 2025 review from the China Academy of Chinese Medical Sciences systematically examines mitochondrial autophagy (mitophagy) as a central anti-aging mechanism. Aging drives mitochondrial dysfunction through ROS accumulation, mtDNA mutations, impaired energy metabolism, and reduced biosynthesis. Two key mitophagy pathways — the ubiquitin-dependent PINK1/Parkin pathway and ubiquitin-independent receptor-mediated pathways (BNIP3, FUNDC1) — normally clear damaged mitochondria, but their efficiency declines with age. This creates a vicious cycle of mitochondrial damage, ROS overproduction, and accelerated aging. Interventions including urolithin A, NMN, caloric restriction, and exercise show promise in restoring mitophagy, though excessive autophagy activation can also be harmful, underscoring the need for precise, tissue-specific regulation.
Detailed Summary
Mitochondrial dysfunction is increasingly recognized as a central driver of aging, contributing to neurodegenerative diseases, cardiovascular pathology, metabolic disorders, and age-related macular degeneration. This comprehensive review synthesizes current understanding of how mitophagy — the selective autophagic removal of damaged mitochondria — governs cellular aging and explores strategies to target it therapeutically.
Aging is characterized by 12 interconnected hallmarks, with mitochondrial dysfunction and declining autophagy forming a core hub. As organisms age, mitochondria accumulate ROS generated by electron transport chain (ETC) dysfunction, accrue mtDNA mutations at rates 10–20 times higher than in youth, exhibit impaired dynamics (reduced fusion proteins OPA1/MFN2, elevated fission protein DRP1), and show downregulated PGC-1α-driven biosynthesis. These defects combine to create a feed-forward loop: damaged mitochondria produce more ROS, which further damages mtDNA and impairs autophagy, accelerating senescence.
Two principal mitophagy pathways are detailed. The PINK1/Parkin ubiquitin-dependent pathway is triggered when mitochondrial membrane potential dissipates — PINK1 kinase accumulates on the outer mitochondrial membrane, phosphorylates ubiquitin, and recruits the E3 ligase Parkin to ubiquitinate OMM substrates, enabling LC3-mediated autophagosome formation via adaptors OPTN and NDP52. The ubiquitin-independent pathway relies on OMM receptor proteins — BNIP3, FUNDC1, NIX, BCL2L13, and FKBP8 — that directly bind LC3 via LIR motifs in response to hypoxia or stress. FUNDC1 in particular is upregulated by exercise training, while BNIP3 can drive mitochondrial fragmentation to facilitate mitophagy.
Key regulatory nodes include the AMPK/mTOR axis: AMPK promotes mitophagy and mitochondrial quality control, while mTOR suppresses autophagy. AMPK activity declines with age, permitting mTOR overactivation and autophagic suppression. Crucially, the relationship is non-linear — sustained AMPK overactivation can also impair mitochondrial homeostasis, illustrating an inverted-U dose-response. NAD⁺ levels, which fall with aging, modulate SIRT1/SIRT3 deacetylase activity influencing mitophagy efficiency; NMN supplementation can partially restore this. Urolithin A enhances PINK1/Parkin signaling and has shown efficacy in preclinical and early clinical settings. Caloric restriction activates the AMPK/SIRT1 axis, while endurance exercise upregulates FUNDC1 and BNIP3 expression.
The review emphasizes mitophagy's double-edged nature: moderate activation clears dysfunctional mitochondria and is anti-aging, but excessive or dysregulated mitophagy can eliminate too many mitochondria, causing metabolic collapse. This is especially relevant in neurons and cardiomyocytes. Gene-editing approaches (mitoTALEN) targeting pathogenic mtDNA mutations are promising but require further in vivo validation before clinical translation. Future research must define tissue-specific autophagic thresholds and dynamic monitoring strategies to enable precise, safe interventions.
Key Findings
- Mitophagy efficiency declines with age, creating a ROS-damage-aging vicious cycle that accelerates neurodegeneration and cardiovascular disease.
- PINK1/Parkin and receptor-mediated (BNIP3/FUNDC1) pathways govern mitophagy; both are impaired during aging.
- AMPK/mTOR balance is critical — moderate AMPK activation promotes mitophagy, but sustained overactivation can be harmful.
- Urolithin A, NMN, caloric restriction, and exercise each restore mitophagy via distinct molecular mechanisms.
- Excessive mitophagy is as dangerous as insufficient mitophagy, demanding tissue-specific, precisely calibrated interventions.
Methodology
This is a narrative review article synthesizing published experimental, clinical, and preclinical literature on mitochondrial autophagy and aging. No original data were generated; conclusions are drawn from integration of mechanistic, animal, and early human intervention studies. The review was conducted by researchers at the China Academy of Chinese Medical Sciences and funded by the Beijing Nova Program.
Study Limitations
As a narrative review, the paper does not perform systematic meta-analysis or quantitative synthesis, limiting ability to compare intervention efficacies. Most mechanistic evidence derives from animal models; human clinical trial data on mitophagy-targeted interventions remain sparse. The review acknowledges that tissue-specific autophagic thresholds and long-term safety of sustained mitophagy activation have not been established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: